HCPs, let us know your thoughts. A 68-year-old male with primary myelofibrosis received ruxolitinib 10 mg twice daily for 7 months. His spleen size and symptoms are controlled, but Hb remains <8 g/dL. EPO, 210 mU/mL; platelets, 85,000/µL. What is your next step?

In our latest expert masterclass, Jean-Jacques Kiladjian, Aaron Gerds, and John Mascarenhas discuss the evolving treatment landscape for #myelofibrosis-related #anemia. https://t.co/EpqzhBmS5V #MPNsm #MPN #MedEd @jjkiladjian @AaronGerds

New publication 📝An exposure–response analysis, published in @BritJClinPharm, shows fedratinib exposure is positively associated with SVR35 and TSS response in patients with #myelofibrosis. Learn more about fedratinib in MF: https://t.co/Wi4m8wkeUL #MPN #MPNsm #MedNews #MedEd

Anemia is a frequent complication in #myelofibrosis. Though momelotinib and pacritinib have meaningful impacts on #anemia, JAKi-based combination therapies may further improve this unmet need. Watch the full video here: https://t.co/oZR2gLmLng #MPNsm #MPN #MedEd @jjkiladjian

In our latest podcast, Jean-Jacques Kiladjian discusses the current unmet needs in the management of #myelofibrosis-associated #anemia. Listen here: https://t.co/6NxRKRip3a #MPNsm #MPN #MedEd @jjkiladjian @HopSaintLouis

New publication 📝 Results from a multicenter Japanese study, published in @FutureOncology, show ruxolitinib demonstrated spleen response and symptom improvement in 26.2% and 52.0% of patients with #myelofibrosis, respectively, at 6 months, with no new safety concerns. Learn

Supportive agents are essential in clinical practice, but the ultimate goal for patients with myelofibrosis and anemia is to develop therapies that fundamentally modify the disease and restore normal blood cell production. Watch the full video here: https://t.co/98zZN66xKy

Emerging therapies for #myelofibrosis-related #anemia target the TGF-β/SMAD pathway and hepcidin modulation. Whether their optimal use is alone, in combination, or at specific stages of anemia remains to be determined. Watch the full video here: https://t.co/C4SHAhHL2i

In our latest podcast, John Mascarenhas discusses what is on the horizon for the treatment of #myelofibrosis-related #anemia. Listen here: https://t.co/1VP9Xbqjtn #MPNsm #MPN #MedEd @IcahnMountSinai

New publication📝Findings published in @LeukemiaJnl show cytoreductive treatment in patients with ET/PV and QRISK3 ≥7.5% conferred a reduced risk of thrombosis vs active surveillance (p = 0.018/0.034). Learn more: https://t.co/MDFRDlaRQ3 #MPNsm #MPN #MedNews #MedEd

The #MPN Hub newsletter provides healthcare professionals with up-to-date global advances in #MPN relating to its classification, diagnosis, treatment, and management. View a previous newsletter: https://t.co/5wkjmV1XTm #mpnsm

Learn more about the emerging treatments for #myelofibrosis-related #anemia with our expert interview, featuring John Mascarenhas. Watch here: https://t.co/C4SHAhHL2i #MPNsm #MPN #MedEd @IcahnMountSinai

Catch up with our latest podcast featuring @AaronGerds, @ClevelandClinic on the unmet needs and latest treatment strategies for myelofibrosis-associated #anemia. https://t.co/oSyPTsp9Pl #MPN #MPNsm #myelofibrosis

The MPN Hub was pleased to speak with John Mascarenhas. We asked, What is on the horizon for the treatment of #myelofibrosis-related #anemia? https://t.co/C4SHAhHL2i #MPNsm #MPN #MedEd @IcahnMountSinai

Catch up on the latest developments in myeloproliferative neoplasms from #IACH, with live social media coverage from the MPN Hub. https://t.co/IF9xfLCGlt #MPN #mpnsm #MedEd #MedNews

New publication 📝 A retrospective study, published in @JClinPath_BMJ, shows machine learning algorithms can predict PV from CBC parameters with high accuracy, potentially reducing need for costly diagnostic methods. Learn more: https://t.co/t0Mn2TURlq #MPN #mpnsm #MedNews

Phase I LIMBER results presented at the EHA2025 Congress demonstrate BET inhibitor INCB057643 produced improvements in anemia, spleen size, and symptom burden for the treatment of patients with MF and other MPN. Read more: https://t.co/JVK6MlMAPj

New publication 📝 A real-world study published in @Haematologica shows momelotinib achieved early and sustained recovery of T and NK cells in patients with MF, with levels comparable to healthy controls. Learn more: https://t.co/ddeEeg9B5R #MPN #mpnsm #MedNews #MedEd

Phase I LIMBER results presented at EHA2025 Congress demonstrate BET inhibitor INCB057643 was generally well tolerated as monotherapy and in combination with ruxolitinib for the treatment of patients with MF and other MPN. Read more: https://t.co/iCD1CZP7za

Learn more about the unmet needs in the management of #myelofibrosis-related #anemia with our expert interview featuring Jean-Jacques Kiladjian. Watch here: https://t.co/oZR2gLmLng #MPNsm #MPN #MedEd @jjkiladjian @Univ_Paris @HopSaintLouis